Effects of probiotics on secondary outcomes
| Effect on Quality of Life | Week 8 | Week 16 | |||
|---|---|---|---|---|---|
| Change in DFIQ* | Probiotic | −2 (−5 to −0.7) | −2.5 (−5 to −1) | ||
| Placebo | −2 (−6 to 2) | −3 (−7.2 to 2) |
| Effect on parental perception of AD | Better | No change | Worse | ||
|---|---|---|---|---|---|
| Reported change | Probiotic | 16 (61) | 8 (31) | 2 (8) | |
| during intervention† | Placebo | 16 (59) | 8 (30) | 3 (11) | |
| Reported change after | Probiotic | 13 (50) | 5 (19) | 8 (31) | |
| ceasing supplementation† | Placebo | 10 (38) | 4 (15) | 12 (46) |
| Yes | No | ||||
|---|---|---|---|---|---|
| Parents would continue | Probiotic | 16 (62) | 10 (38) | ||
| supplementation† | Placebo | 19 (73) | 7 (27) |
| Effect on medication use | Week 2 | Week 4 | Week 8 | Week 16 | |
|---|---|---|---|---|---|
| *Values are presented as medians (25th percentile to 75th percentile). Change in DFIQ and topical corticosteroid use is the difference from baseline. DFIQ, Dermatitis Family Impact Questionnaire; †values are frequency (percentage); ‡corticosteroid use calculated from number of applications per week multiplied by potency. | |||||
| Change in topical | Probiotic | 0 (−4 to 0.7) | 0 (−6.5 to 3.7) | 0.25 (−6.7 to 7) | 0 (−8.4 to 6.4) |
| corticosteroid use*‡ | Placebo | 0 (−4 to 0) | 0 (−6 to 0) | −1 (−8 to 0.7) | 0 (−9 to 0.7) |
| Number of children | Probiotic | 3 (11) | 1 (4) | 4 (15) | 6 (23) |
| taking antibiotics† | Placebo | 2 (7) | 3 (11) | 7 (26) | 6 (22) |